The data presented here establish that the NT-proBNP response, defined as a decrease in NT-proBNP of >30% and >300 ng/l (35.4 pmol/l), predicts clinical outcome and survival and is a validated and qualified surrogate marker of efficacy for interventions for patients with AL amyloidosis. The gene discussed is NPPB; the disease is AL amyloidosis.